What does a serum free kappa light chain level of 27.3 mg/L indicate and what are the appropriate next steps for evaluation?

Serum Free Kappa Light Chain Level of 27.3 mg/L: Interpretation and Next Steps

A serum free kappa light chain level of 27.3 mg/L is elevated above the normal range (1.6-15.2 mg/L) and requires immediate evaluation of the kappa/lambda free light chain ratio to determine if this represents a monoclonal process, followed by comprehensive workup for plasma cell disorders or AL amyloidosis. 1

Immediate Assessment Required

Calculate the Free Light Chain Ratio

• The kappa/lambda ratio is the critical determinant of clonality 2, 3
• Normal ratio range: 0.26-1.65 (FreeLite assay) or 0.31-1.56 (Siemens assay) 4, 3
• An abnormal ratio (>1.65 or <0.26) indicates clonal plasma cell expansion and mandates further investigation 2, 3
• Important caveat: Renal impairment alters the normal range to 0.34-3.10 in severe renal failure (CKD stage 5), as free light chains are cleared by the kidney 3

Complete the Monoclonal Protein Workup

Perform these tests immediately to screen for plasma cell disorders: 5, 6, 5

• Serum protein electrophoresis (SPEP) with immunofixation - detects intact monoclonal immunoglobulins 5
• 24-hour urine protein electrophoresis with immunofixation - quantifies Bence Jones proteinuria 5
• Quantitative immunoglobulins (IgG, IgA, IgM) - assesses for heavy chain monoclonal protein 5

Risk Stratification Based on FLC Ratio

If Kappa/Lambda Ratio is Abnormal (>1.65)

This indicates a kappa-producing clone. Proceed with: 2, 7

Bone marrow evaluation: 5, 8, 5

• Bone marrow aspiration and biopsy to quantify clonal plasma cells
• Cytogenetics and FISH studies for risk stratification 5
• Immunophenotyping 5

End-organ damage assessment (CRAB criteria): 5, 8, 5

• Calcium: serum calcium >11.5 mg/dL or >1 mg/dL above upper limit of normal 8
• Renal: creatinine >2 mg/dL or creatinine clearance <40 mL/min 8
• Anemia: hemoglobin <10 g/dL or >2 g/dL below lower limit of normal 8
• Bone lesions: skeletal survey (spine, pelvis, skull, humeri, femora) 5

Additional myeloma-defining events: 8

• Clonal bone marrow plasma cells ≥60%
• Abnormal serum FLC ratio ≥100 (involved kappa)

• 1 focal lesion ≥5 mm on MRI

Diagnostic Categories Based on Findings

Light Chain MGUS (if all criteria met): 2

• Abnormal FLC ratio with increased kappa FLC
• No immunoglobulin heavy chain on immunofixation
• Clonal bone marrow plasma cells <10%
• Absence of CRAB features

Smoldering Multiple Myeloma: 5, 8, 5

• Serum monoclonal protein ≥3 g/dL and/or clonal bone marrow plasma cells ≥10%
• Absence of CRAB features or other myeloma-defining events

Active Multiple Myeloma: 5, 8, 5

• Clonal bone marrow plasma cells ≥10% or biopsy-proven plasmacytoma
• PLUS any myeloma-defining event (CRAB criteria or biomarkers listed above)

Special Considerations

AL Amyloidosis Screening

This is critical because AL amyloidosis has >99% sensitivity for elevated NT-proBNP and requires urgent hematology referral: 4, 6

Screen for cardiac involvement if patient has: 4, 6

• Unexplained heart failure with preserved ejection fraction
• Increased LV wall thickness >12 mm without other cause
• Peripheral neuropathy or dysautonomia
• History of bilateral carpal tunnel syndrome

Obtain: 4, 6

• NT-proBNP (≥332 ng/L suggests cardiac involvement)
• Troponin T
• Echocardiogram if cardiac symptoms present

Renal Function Impact

• Check serum creatinine before interpreting FLC ratio 3
• Mild renal impairment can elevate both kappa and lambda proportionally, preserving the ratio 3
• Use adjusted reference ranges if CKD stage 5 present 3

Monitoring Strategy if Low-Risk MGUS Confirmed

If diagnosed with low-risk light chain MGUS (FLC ratio only mildly abnormal, <10% plasma cells, no CRAB): 7

• Follow-up every 2-3 years or at time of clinical progression
• Monitor for symptoms: bone pain, fatigue, recurrent infections, renal dysfunction 7

If high-risk features present (FLC ratio ≥8 or ≤0.125 with ≥10% plasma cells): 7

• Risk of progression 10% per year in first 2 years
• Consider clinical trial enrollment for chemoprevention 7
• Close monitoring every 3-6 months 7

Common Pitfalls to Avoid

• Never rely on absolute FLC levels alone - the ratio is what determines clonality 2, 3
• Always use the same assay method for serial monitoring - FreeLite and Siemens assays are not interconvertible 3
• Do not skip urine studies if AL amyloidosis suspected - 24-hour urine collection remains necessary for AL diagnosis 9
• Recognize that normal SPEP/immunofixation does not exclude disease - light chain-only disorders may have no heavy chain expression 2, 9